|Awarded On||March 29, 2012|
|Title||TexCITE (Texas Cancer ImmunoTherapy Enterprise): Focused development of innovative cell therapies for cancer|
|Program||Product Development Research|
|Award Mechanism||Company Relocation|
|Principal Investigator/Program Director||Gregg Sando|
|Cancer Sites||Lymphoma, Other|
Cell Medica is a leader in the development of cellular immunotherapy for cancer applications. Cell Medica is applying for a Relocation Award to achieve FDA approval for two cell therapies: Cytorex EBV for the treatment of cancers associated with the Epstein Barr virus (EBV) and Cytovir CMV for cytomegalovirus (CMV) infections in patients following bone marrow transplant.
Support for Cytorex EBV fits with CPRIT’s mission to foster new therapies for cancer treatment. 1) Cellular immunotherapies provide powerful tools for the treatment of cancer and Cytorex EBV is a breakthrough for patients with EBV-associated cancers. 2) The safety of Cytorex EBV will improve long-term outcomes allowing treat...